#USA #Pleasant Grove, Utah #Mayo Clinic #Neurolens #Renew Biotechnologies

Renew Biotechnologies and Mayo Clinic Collaboration

Renew Biotechnologies has taken a significant step in advancing neuroimmunologic disease research by partnering with the esteemed Mayo Clinic. The focus of this collaboration is to evaluate NeuroLens®, a pioneering approach based on cell-free DNA (cfDNA). This innovative technology aims to enhance the understanding of multiple sclerosis (MS) and related neuroimmunologic diseases, which have long posed challenges to patient care and treatment efficacy.

The Need for Innovative Biomarkers

The primary motivation behind this partnership stems from the pressing need for non-invasive biomarkers. These biomarkers can offer crucial insights into the dynamics of active central nervous system (CNS) injury, paving the way for more personalized and informed patient care. As medical professionals seek to understand how these injuries evolve over time, NeuroLens® promises to deliver the necessary molecular insights required.

Building on Previous Research

Renew Biotechnologies is not new to this field; they have previously conducted valuable research regarding Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. The new study will focus on the cfDNA cell-of-origin signatures that correlate with cellular death across various clinically characterized neuroimmunologic diseases. By scrutinizing injury signatures from neurons, astrocytes, and oligodendroglial cells, the research aims to link these signals to disease differentiation, severity, and progression.

Contributions from Mayo Clinic

Under this collaboration, Mayo Clinic offers its wealth of clinical expertise and access to well-structured biorepository resources. These assets are expected to inform the design of studies that are clinically meaningful and to assist in identifying relevant clinical proof points. Notably, Mayo Clinic's resources will provide the characterized samples needed to evaluate the relationship between NeuroLens® signals and disease presentation throughout the research phase.

Chad Pollard, Co-Founder and CEO of Renew Biotechnologies, emphasized the importance of this collaboration, stating, "Complex neurological diseases present clinical questions that require both strong molecular tools and deep clinical context. Working with Mayo Clinic will help us explore new applications for NeuroLens, and provide insights as we seek to expand its potential to benefit patients across a broader range of neurological diseases."

Goals and Future Directions

The research endeavor will initially concentrate on multiple sclerosis but has the potential for expansion into other neuroimmunologic diseases based on the study's criteria. Investigators will explore relationships between the cell-of-origin signals and various factors including disease phenotype, progression, treatment response, and levels of disability over time. This comprehensive understanding may eventually lead to more refined disease assessment methodologies and improved patient management strategies.

About Renew Biotechnologies

Renew Biotechnologies is recognized as a pioneering translational diagnostics company. Its mission is centered on decoding disease-specific molecular signals, which plays a crucial role in advancing research and therapeutic development. Their integrated approach combines top-tier laboratory operations with proprietary assay development, multi-omics sequencing, and cutting-edge bioinformatics technologies. As the company continues its commitment to innovative research in neurology, oncology, and other complex diseases, this partnership with Mayo Clinic signifies a promising advancement in the realms of diagnostics and patient care.

For further information, interested parties are encouraged to visit Renew Biotechnologies' official website.